Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)

被引：13

作者：

Lai-Kwon, Julia ^{[1
]}

Kelly, Brooke ^{[2
]}

Lane, Sarah ^{[1
]}

Biviano, Rebecca ^{[1
]}

Bartula, Iris ^{[1
,3
]}

Brennan, Frank

Kivikoski, Ingrid

Thompson, Jake ^{[1
]}

Dhillon, Haryana M. ^{[4
,5
]}

Menzies, Alexander ^{[1
,3
,6
,7
]}

Long, Georgina, V ^{[1
,3
,6
,7
]}

机构：

[1] Melanoma Inst Australia, Sydney, NSW, Australia

[2] Melanoma Patients Australia, Varsity Lakes, Australia

[3] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia

[4] Univ Sydney, Fac Sci, Sch Psychol, Ctr Med Psychol & Evidence Based Decis Making, Sydney, NSW, Australia

[5] Univ Sydney, Fac Sci, Sch Psychol, Psychooncol Cooperat Grp, Sydney, NSW, Australia

[6] Royal North Shore Hosp, Sydney, NSW, Australia

[7] Mater Hosp, Sydney, NSW, Australia

来源：

SUPPORTIVE CARE IN CANCER | 2022年 / 30卷 / 11期

关键词：

Melanoma; Survivorship; Nursing; Telehealth; Quality of life; RANDOMIZED CONTROLLED-TRIAL; DISTRESS; OUTCOMES; MODEL; CARE; DISCONTINUATION;

D O I：

10.1007/s00520-022-07360-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. We assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group. Methods: People >= 18 years diagnosed with unresectable stage III or stage IV melanoma who were >= 6 months post initiation of ICI/TT with a radiological response suggestive of a long-term response to ICI/TT were recruited from a specialist melanoma centre in Australia. All participants received MELCARE, a nurse-led survivorship program involving two telehealth consultations 3 months apart, needs assessment using the Distress Thermometer (DT) and Problem List, and creation of a survivorship care plan. Feasibility, acceptability, and utility were assessed using rates of consent and study completion, time taken to complete each component of MELCARE, the Acceptability of Intervention Measure (AIM), and a customised utility survey. Results: 31/54 (57%) people consented. Participants were male (21, 68%), with a median age of 67 (range: 46-82). Eleven (35%) were receiving/had received ipilimumab and nivolumab and 27 (87%) had ceased treatment. Feasibility was demonstrated with 97% completing MELCARE. Utility was demonstrated on a customised survey and supported by a reduction in the mean DT score (initial: 5.6, SD: 2.9; follow-up: 1.5, SD: 1.2). Acceptability was demonstrated on 3/4 AIM items. Conclusion: MELCARE was feasible and acceptable with high levels of utility. However, the consent rate was 57% indicating some people do not require support. Future studies should consider MELCARE's optimal timing, resourcing, and cost-effectiveness.

引用

页码：9587 / 9596

页数：10